Spigaglia P, Mastrantonio P, Barbanti F
Adv Exp Med Biol. 2024; 1435:169-198.
PMID: 38175476
DOI: 10.1007/978-3-031-42108-2_9.
Etifa P, Rodriguez C, Harmanus C, Sanders I, Sidorov I, Mohammed O
Antibiotics (Basel). 2023; 12(3).
PMID: 36978302
PMC: 10044524.
DOI: 10.3390/antibiotics12030435.
Piepenbrock E, Stelzer Y, Berger F, Jazmati N
Curr Microbiol. 2019; 76(4):520-526.
PMID: 30805700
DOI: 10.1007/s00284-019-01654-3.
Sukumar M, Konig B
Infect Drug Resist. 2018; 11:2357-2362.
PMID: 30532567
PMC: 6247965.
DOI: 10.2147/IDR.S163484.
Maass S, Otto A, Albrecht D, Riedel K, Trautwein-Schult A, Becher D
Cells. 2018; 7(11).
PMID: 30445773
PMC: 6262375.
DOI: 10.3390/cells7110213.
Epidemiological and genomic characterization of community-acquired Clostridium difficile infections.
Thornton C, Rubin J, Greninger A, Peirano G, Chiu C, Pillai D
BMC Infect Dis. 2018; 18(1):443.
PMID: 30170546
PMC: 6119286.
DOI: 10.1186/s12879-018-3337-9.
Recombinant Mucin-Type Fusion Proteins with a Galα1,3Gal Substitution as Clostridium difficile Toxin A Inhibitors.
Cherian R, Jin C, Liu J, Karlsson N, Holgersson J
Infect Immun. 2016; 84(10):2842-52.
PMID: 27456831
PMC: 5038087.
DOI: 10.1128/IAI.00341-16.
Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection.
Baines S, Wilcox M
Antibiotics (Basel). 2016; 4(3):267-98.
PMID: 27025625
PMC: 4790285.
DOI: 10.3390/antibiotics4030267.
Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection.
Spigaglia P
Ther Adv Infect Dis. 2016; 3(1):23-42.
PMID: 26862400
PMC: 4735502.
DOI: 10.1177/2049936115622891.
Routine disc diffusion antimicrobial susceptibility testing of Clostridium difficile and association with PCR ribotype 027.
Holt H, Danielsen T, Justesen U
Eur J Clin Microbiol Infect Dis. 2015; 34(11):2243-6.
PMID: 26319148
DOI: 10.1007/s10096-015-2475-x.
Impact of clinical awareness and diagnostic tests on the underdiagnosis of Clostridium difficile infection.
Alcala L, Reigadas E, Marin M, Martin A, Catalan P, Bouza E
Eur J Clin Microbiol Infect Dis. 2015; 34(8):1515-25.
PMID: 25904126
DOI: 10.1007/s10096-015-2380-3.
In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile.
Corbett D, Wise A, Birchall S, Warn P, Baines S, Crowther G
J Antimicrob Chemother. 2015; 70(6):1751-6.
PMID: 25652750
PMC: 4498293.
DOI: 10.1093/jac/dkv006.
SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model.
Baines S, Crowther G, Freeman J, Todhunter S, Vickers R, Wilcox M
J Antimicrob Chemother. 2014; 70(1):182-9.
PMID: 25190720
PMC: 4267497.
DOI: 10.1093/jac/dku324.
Proteomic analysis of a NAP1 Clostridium difficile clinical isolate resistant to metronidazole.
Chong P, Lynch T, McCorrister S, Kibsey P, Miller M, Gravel D
PLoS One. 2014; 9(1):e82622.
PMID: 24400070
PMC: 3882210.
DOI: 10.1371/journal.pone.0082622.
Molecular epidemiology of Clostridium difficile strains from nosocomial-acquired infections.
Corbellini S, Piccinelli G, De Francesco M, Ravizzola G, Bonfanti C
Folia Microbiol (Praha). 2013; 59(2):173-9.
PMID: 24081935
DOI: 10.1007/s12223-013-0281-3.
Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories.
Burnham C, Carroll K
Clin Microbiol Rev. 2013; 26(3):604-30.
PMID: 23824374
PMC: 3719497.
DOI: 10.1128/CMR.00016-13.
Studies with bioengineered Nisin peptides highlight the broad-spectrum potency of Nisin V.
Field D, Quigley L, OConnor P, Rea M, Daly K, Cotter P
Microb Biotechnol. 2011; 3(4):473-86.
PMID: 21255345
PMC: 3815813.
DOI: 10.1111/j.1751-7915.2010.00184.x.
The changing epidemiology of Clostridium difficile infections.
Freeman J, Bauer M, Baines S, Corver J, Fawley W, Goorhuis B
Clin Microbiol Rev. 2010; 23(3):529-49.
PMID: 20610822
PMC: 2901659.
DOI: 10.1128/CMR.00082-09.
Anaerobic infections: update on treatment considerations.
Nagy E
Drugs. 2010; 70(7):841-58.
PMID: 20426496
DOI: 10.2165/11534490-000000000-00000.
Neutralization of Clostridium difficile toxin A using antibody combinations.
Demarest S, Hariharan M, Elia M, Salbato J, Jin P, Bird C
MAbs. 2010; 2(2):190-8.
PMID: 20150758
PMC: 2840238.
DOI: 10.4161/mabs.2.2.11220.
